Trial Profile
Phase I Trial to Assess the Safety and Pharmacokinetics of GP2013 Monotherapy Administered Weekly in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications B-cell lymphoma
- Focus Pharmacokinetics
- Sponsors Sandoz
- 08 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Sep 2013 New trial record